Most Recent
Animal drug giant Merial is pushing on with its opposition to rival Intervet's bid to a patent a non-drug resistant injectable formula for treating animal parasites, filing an appeal in the Federal Court after it came up short in its challenge before IP Australia.
A court has struck out defamation claims brought by embattled Quintis founder Frank Wilson against the company's former directors over ASX statements he alleges suggested he knew about the company's termination of a supply contract with Nestle's dermatology unit, Galderma Laboratories.
Mercy Hospital for Women in Melbourne can give a pregnant 17-year-old Jehovah's witness a blood transfusion if her life is at risk during or after childbirth, a judge has found, despite the girl's refusal to consent on religious grounds.
ObjectiVision has presented a "limited" and "debatable" case that its source code for a glaucoma testing device was copied, the Federal Court heard Thursday as the trial in a four-year spat with the University of Sydney over IP rights came to a close.
TPI Enterprises has gone on the offensive in a patent lawsuit initiated by rival poppy processor Tasmanian Alkaloids, saying the patents at the centre of the suit describe natural parts that can't be patented.
Two hearing aid companies have agreed to pay a $2.5 million penalty over ads that misled pensioners about benefits available under the government's Hearing Services Program, and the ACCC has warned another enforcement action against a hearing aid company is imminent.
Plaintiffs law firm Slater & Gordon is considering a class action against gynaecologist Dr. Emil Gayed, who was found guilty of professional misconduct after patients complained of undergoing unnecessary surgery and not giving informed consent to procedures.
Biologics company Cryosite has denied claims by the ACCC that it engaged in cartel conduct by referring customers to Cell Care before their asset sale agreement was completed, saying the two were not competitors.
Concerns that the proposed acquisition of Sirtex Medical by a Chinese private equity firm would leave the company with insufficient funds to cover a settlement or judgement in a class action were eased Wednesday, after a barrister said the takeover would leave the company with just under $1 billion in assets.
The company that manufactures Botox alternatives has denied infringing on Allergan's Botox trade mark, telling a court Wednesday its use of the word was for comparative purposes only.